U:  P:        Forgot Password? Username?

Physician Registration


medical_05


Current Trials

Pulmonary Cystic Fibrosis Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis PDF Print E-mail
  • This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations.
  • For Children up to 18 years of age.
< Prev   Next >
 
Privacy PolicyTerms of ServiceLogin